Serum alpha-fetoprotein predicts treatment outcome in chronic hepatitis C patients regardless of HCV genotype.
We examined the association between serum alpha-fetoprotein (AFP) level and sustained virological response (SVR) in 93 chronic hepatitis C patients. The SVR rate was much higher among patients with serum AFP levels below rather than above the median value (5.7 ng/ml) (58.7% and 19.2%, respectively; P<0.0001). Serum AFP should be added to the list of factors predictive of treatment response in chronic hepatitis C.
Unité d'Epidémiologie des Maladies Emergentes, Institut Pasteur, Paris, France.
Hendy
H
Abdoul
Vincent
V
Mallet
Stanislas
S
Pol
Arnaud
A
Fontanet
D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000097:blood* / Q000821:virology; D006801:Humans; D012189:Retrospective Studies; D016896:Treatment Outcome; D000509:alpha-Fetoproteins / Q000032:analysis*
D000509:alpha-Fetoproteins